Completed PHASE1/PHASE2 INTERVENTIONAL NCT00117247
A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects
A Study to Assess the Pharmacokinetics and Pharmacodynamics of Repeat-Sose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects
Sponsor: Amgen
Conditions
Anemia Congestive Heart Failure
Interventions
darbepoetin alfa
Updated 1 time since 2024 Last updated: Oct 15, 2009 Started: Jun 30, 2002 Completion: Jul 31, 2004
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE1/PHASE2 clinical study on Anemia and Congestive Heart Failure, this trial is completed. The trial is conducted by Amgen and has accumulated 1 data snapshot since 2002. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
1 version recorded Completed — PHASE1/PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Amgen
Data source: Amgen
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.